329 results on '"Unterrainer M."'
Search Results
2. In response to: Anatomy of 18F-GE180, a failed radioligand for the TSPO protein
3. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study
4. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
5. EP08.02-14 Prognostic Role of Baseline PET/CT Parameters in Frail Patients with Inoperable Node-Positive Stage IIB-IIIC/Recurrent NSCLC
6. A look ahead: future directions of SSR-directed imaging and therapy in meningioma
7. Current status of SSR-directed imaging and therapy in meningioma
8. Recent advances of PET imaging in clinical radiation oncology
9. Biological tumour volumes of gliomas in early and standard 20–40 min 18F-FET PET images differ according to IDH mutation status
10. PD-0567 CT-based radiomic signatures to predict biochemical recurrence after salvage radiotherapy
11. PD-0969 FDG PET/CT follow up imaging of durvalumab maintenance in inoperable stage III NSCLC patients
12. Analyse der Diskordanz bildgebender Response Kriterien bei Lymphomen unter CAR-T-Zell-Therapie
13. PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma
14. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
15. Ansätze zur Volumenbestimmung von Meningeomen in der PET/CT Bildgebung mit dem neuartigen Tracer F-18-SiTATE
16. Diverging metabolic patterns on [18F]FDG PET/CT in inoperable stage III NSCLC patients undergoing anti-PD-L1 checkpoint inhibition with durvalumab
17. First clinical results of [68Ga]Ga-FAPI-46 PET/CT in squamous penile cancer
18. TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma
19. Serial TSPO and FET PET monitoring in experimental orthotopic glioblastoma and the impact of inflammation and astrogliosis related to the inoculation process
20. Feasibility of 68Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in urothelial carcinoma
21. Biological-tumour-volumes in standard and early summation 18F-FET PET images distinctly exceed contrast-enhancement in patients with IDH-wildtype glioblastoma
22. PSMA-expression is highly associated with histological subtypes of renal cell carcinoma – an immunohistochemical nephrectomy study
23. Prognostische Wertigkeit der TSPO-PET bei Patienten mit Gliomrezidiv
24. Re: Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging Trial
25. Feasibility of 68Ga-FAPI-46 PET/CT for detection of metastatic spread in urothelial carcinoma
26. Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas
27. 18F-GE-180 TSPO PET in High-Grade Glioma RT Planning
28. Correction to: Biological tumour volumes of gliomas in early and standard 20–40 min 18F-FET PET images differ according to IDH mutation status
29. PO-1195 Residual MTV after chemoradiotherapy ± immune checkpoint inhibition for inoperable stage III NSCLC
30. Impact of TSPO polymorphism on [18F]GE-180binding in healthy and pseudoreference tissue of neurooncological and neurodegenerative disorders
31. Feasibility of different tumor delineation approaches for 18F-PSMA-1007 PET/CT imaging in patients with metastatic prostate cancer
32. Dosimetry and optimal time frame of [18F]SiTATE PET/CT in Patients with Neuroendocrine Carcinoma
33. Dual-phase beta-amyloid PET for assessment of neuronal injury and amyloidosis in corticobasal syndrome
34. 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results
35. Advanced Molecular Imaging in Histologically Verified Metanephric Adenoma
36. Extrahierung von Histogramm- und Textureigenschaften aus parametrischen F-18-FET PET Bildern zur molekulargenetischen und histologischen Klassifizierung von Gliomen
37. Dual-phase β-Amyloid PET for Assessment of Neuronal Injury and Amyloidosis in Corticobasal Syndrome
38. Perfusion-Phase 18 F-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neuronal Injury
39. 18 F-FET PET uptake characteristics of long-term IDH-wildtype glioma survivors
40. Prognostic value of 18F-GE-180 PET in newly diagnosed IDH-wildtype glioma prior to radiotherapy
41. Utility of bone scintigraphy during the course of radium-223 treatment in mCRPC patients
42. 99 m Tc-antigranulocyte scintigraphy for estimation of bone marrow reserve prior to PSMA-radioligand therapy
43. Does the expression of L-type amino acid transporters 1 (LAT1) differ between 18 F-FET-positve and 18 F-FET-negative gliomas?
44. Whole-brain connectivity as a measure for disease burden – moving beyond structure and towards function in MRI imaging of glioma patients
45. A0911 - Feasibility of 68Ga-FAPI-46 PET/CT for detection of metastatic spread in urothelial carcinoma
46. Left Temporal Hypometabolism in FDG-PET underlines Cognitive Reserve Hypothesis in Frontotemporal Dementia
47. Neuronal Injury Biomarkers for Assessment of Cognitive Reserve in Alzheimer’s Disease
48. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
49. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study
50. 18f-Rhpsma-7 Positron Emission Tomography (PET) for the Detection of Biochemical Recurrence after Primary Radiation Therapy of Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.